Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The PACIFIC trial's consolidation durvalumab after chemoradiotherapy has long been the gold standard for unresectable stage III NSCLC — but a wave of phase 3 trials is challenging that status quo. From ctDNA-guided therapy escalation and de-escalation to induction chemoimmunotherapy and smarter radiation planning, the field is rapidly evolving. Early data suggest most patients can still reach definitive therapy with induction approaches, with promising survival signals.
The PACIFIC trial established consolidation durvalumab after concurrent chemoradiotherapy as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC) — but at least eight ongoing phase 3 trials are now testing whether that benchmark can be beaten. Strategies range from adding KRAS G12C inhibitors or PD-1/VEGF bispecific antibodies to durvalumab, to novel radiotherapy approaches like stereotactic body radiation therapy (SBRT) and proton vs. photon chemoradiotherapy.
One of the most exciting frontiers is using circulating tumor DNA (ctDNA) to personalize consolidation therapy. The ADAPT-C trial escalates treatment for patients who remain MRD-positive during consolidation, while the IDEATION trial takes the opposite approach — asking whether ctDNA-negative patients can safely skip durvalumab altogether. Meanwhile, the phase 2 MDT-BRIDGE trial showed that induction durvalumab plus chemotherapy allowed 92% of patients to still receive definitive therapy, with a strong 12-month PFS rate of 85% in those who went on to chemoradiotherapy.
Key Takeaways:
Why it matters: These emerging strategies could fundamentally personalize how unresectable stage III NSCLC is treated — moving from a one-size-fits-all approach to one guided by molecular data, tumor response, and individual risk profiles.